Skip to main content

PESCANDO EN EL INTERACTOMA: DESARROLLO DE NUEVOS ANTIMICROBIANOS CONTRA LA INFECCION POR PSEUDOMONAS AERUGINOSA

PRE2018-083243

•
Funding agency name Agencia Estatal de Investigación
Funding agency acronym AEI
Program Programa Estatal de Promoción del Talento y su Empleabilidad en I+D+i
Subprogram Subprograma Estatal de Formación
Call Contratos Predoctorales
Call year 2018
State Plan 2017-2020 Plan Estatal de Investigación Científica y Técnica y de Innovación
Beneficiary centre UNIVERSIDAD AUTONOMA DE BARCELONA

Resultados relacionados

Resultados totales (Incluyendo duplicados): 3
Encontrada(s) 1 página(s)

DIGITAL.CSIC. Repositorio Institucional del CSIC
Publication Artículo científico (JournalArticle)

Mining the heparinome for cryptic antimicrobial peptides that selectively kill Gram-negative bacteria

  • Bello-Madruga, Roberto
  • Sandín, Daniel
  • Valle, Javier
  • Gómez, Jordi
  • Comas, Laura
  • Larrosa, María Nieves
  • González-López, Juan José
  • Jiménez, M. Angeles
  • Andreu, David
  • Torrent, Marc
Glycosaminoglycan (GAG)-binding proteins regulating essential processes such as cell growth and migration are essential for cell homeostasis. As both GAGs and the lipid A disaccharide core of Gram-negative bacteria contain negatively charged disaccharide units, we hypothesized that GAG-binding proteins could also recognize LPS and enclose cryptic antibiotic motifs. Here, we report novel antimicrobial peptides (AMPs) derived from heparin-binding proteins (HBPs), with specific activity against Gram-negative bacteria and high LPS binding. We used computational tools to locate antimicrobial regions in 82% of HBPs, most of those colocalizing with putative heparin-binding sites. To validate these results, we synthesized five candidates [HBP-1-5] that showed remarkable activity against Gram-negative bacteria, as well as a strong correlation between heparin and LPS binding. Structural characterization of these AMPs shows that heparin or LPS recognition promotes a conformational arrangement that favors binding. Among all analogs, HBP-5 displayed the highest affinity for both heparin and LPS, with antimicrobial activities against Gram-negative bacteria at the nanomolar range. These results suggest that GAG-binding proteins are involved in LPS recognition, which allows them to act also as antimicrobial proteins. Some of the peptides reported here, particularly HBP-5, constitute a new class of AMPs with specific activity against Gram-negative bacteria., Financial support from the Spanish Ministry of Economy and Innovation (PDC2021-121544-I00 funded by MCIN/AEI/10.13039/501100011033 and European Union Next Generation EU/ PRTR to MT; project PID2020-114627RB-I00 funded by MCIN/AEI/10.13039/501100011033 to MT; PID2020-112821GB-I00 funded by MCIN/AEI/10.13039/501100011033 to MAJ and PID2020-113184RB-C22 to DA), the Departament de Recerca iUniversitats de la Generalitat de Catalunya (2023PROD00021 to MT), and from La Caixa Banking Foundation (HR17-00409, to DA). This work has been co-financed by the Spanish Ministry of Science and Innovation with funds from the European Union Next Generation EU, from the Recovery, Transformationand Resilience Plan (PRTR-C17.I1), European Society of Clinical Microbiologyand Infectious Diseases (ESCMID) ESCMID2022 and from the Autonomous Community of Catalonia within the framework of the Biotechnology PlanApplied to Health. Work at UPF was funded by the MCI María de Maeztu network of Units of Excellence. NMR experiments were performed in the“Manuel Rico” NMR laboratory (LMR) of the Spanish National ResearchCouncil (CSIC), a node of the Spanish Large-Scale National Facility (ICTS R-LRB). DS and RBM are recipients of pre-doctoral a FPI scholarship (PRE2018-083243 and PRE2021-097678, respectively) from the Spanish Ministry ofScience and Innovation, Peer reviewed
Dipòsit Digital de Documents de la UAB
Publication Artículo científico (JournalArticle)

Rationally Modified Antimicrobial Peptides from the N-Terminal Domain of Human RNase 3 Show Exceptional Serum Stability

  • Sandín, Daniel|||0000-0002-2805-0208
  • Valle García, Javier|||0000-0002-6787-8286
  • Chaves-Arquero, Belén
  • Prats-Ejarque, Guillem|||0000-0002-8213-4947
  • Larrosa, María Nieves|||0000-0001-8808-0233
  • González-López, Juanjo|||0000-0003-2419-5909
  • Jiménez, María Ángeles|||0000-0001-6835-5850
  • Boix, Ester|||0000-0003-1790-2142
  • Andreu Martínez, David|||0000-0002-6317-6666
  • Torrent, Marc|||0000-0001-6567-3474
Multidrug resistance against conventional antibiotics poses an important threat to human health. In this context, antimicrobial peptides (AMPs) have been extensively studied for their antibacterial activity and promising results have been shown so far. However, AMPs tend to be rather vulnerable to protease degradation, which offsets their therapeutic appeal. Here, we demonstrate how replacing functional residues in the antimicrobial region of human RNase 3-also named eosinophil cationic protein-by non-natural amino acids increases stability in human serum. These changes were also shown to reduce the hemolytic effect of the peptides in general terms, whereas the antimicrobial activity was reasonably preserved. Digestion profiles enabled us to design new peptides with superior stability and lower toxicity that could become relevant candidates to reach clinical stages.
Dipòsit Digital de Documents de la UAB
Publication Artículo científico (JournalArticle)

Antimicrobial Peptides Can Generate Tolerance by Lag and Interfere with Antimicrobial Therapy

  • Sandín, Daniel|||0000-0002-2805-0208
  • Valle García, Javier|||0000-0002-6787-8286
  • Morata, Jordi|||0000-0002-6146-4322
  • Andreu Martínez, David|||0000-0002-6317-6666
  • Torrent, Marc|||0000-0001-6567-3474
Antimicrobial peptides (AMPs) are widely distributed molecules secreted mostly by cells of the innate immune system to prevent bacterial proliferation at the site of infection. As with classic antibiotics, continued treatment with AMPs can create resistance in bacteria. However, whether AMPs can generate tolerance as an intermediate stage towards resistance is not known. Here, we show that the treatment of Escherichia coli with different AMPs induces tolerance by lag, particularly for those peptides that have internal targets. This tolerance can be detected as different morphological and physiological changes, which depend on the type of peptide molecule the bacterium has been exposed to. In addition, we show that AMP tolerance can also affect antibiotic treatment. The genomic sequencing of AMP-tolerant strains shows that different mutations alter membrane composition, DNA replication, and translation. Some of these mutations have also been observed in antibiotic-resistant strains, suggesting that AMP tolerance could be a relevant step in the development of antibiotic resistance. Monitoring AMP tolerance is relevant vis-á-vis the eventual therapeutic use of AMPs and because cross-tolerance might favor the emergence of resistance against conventional antibiotic treatments.